<DOC>
	<DOC>NCT00874887</DOC>
	<brief_summary>The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.</brief_summary>
	<brief_title>A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Male or Female At least 50 years of age In good general health Any ocular surgery or use of topical antibiotics or antiseptics in either eye within the last 3 months Use of topical steroids, or nonsteroidal anti inflammatory drugs in either eye within 30 days of Baseline (or anticipated during the study) Use of lid scrubs within 7 days of Baseline in either eye (or anticipated use during the study)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>